PTC Therapeutics (NASDAQ:PTCT) Given New $77.00 Price Target at Royal Bank Of Canada

PTC Therapeutics (NASDAQ:PTCT) had its price objective lifted by Royal Bank Of Canada from $75.00 to $77.00 in a research report sent to investors on Friday morning,Benzinga reports. Royal Bank Of Canada currently has a sector perform rating on the biopharmaceutical company’s stock.

PTCT has been the subject of several other reports. Barclays boosted their target price on shares of PTC Therapeutics from $120.00 to $122.00 and gave the company an “overweight” rating in a research report on Friday, August 14th. Leerink Partners initiated coverage on shares of PTC Therapeutics in a research report on Monday, September 14th. They issued an “outperform” rating and a $98.00 price target on the stock. Wall Street Zen cut shares of PTC Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 10th. Truist Financial assumed coverage on shares of PTC Therapeutics in a research note on Friday, October 16th. They set a “hold” rating and a $62.00 price target on the stock. Finally, UBS Group initiated coverage on shares of PTC Therapeutics in a research report on Thursday, October 15th. They set a “buy” rating and a $90.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $95.64.

PTC Therapeutics Stock Down 7.0%

PTC Therapeutics stock opened at $59.97 on Friday. PTC Therapeutics has a 52-week low of $58.80 and a 52-week high of $90.87. The company has a market cap of $5.01 billion, a P/E ratio of -42.84, a P/E/G ratio of 1.95 and a beta of 0.49. The business has a 50-day simple moving average of $65.36 and a two-hundred day simple moving average of $70.78.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of $0.14 by ($0.76). The firm had revenue of $357.81 million for the quarter, compared to analysts’ expectations of $306.43 million. During the same quarter in the previous year, the business earned $0.20 EPS. The firm’s revenue for the quarter was up 69.6% on a year-over-year basis. Research analysts anticipate that PTC Therapeutics will post 1.19 EPS for the current fiscal year.

Insider Buying and Selling

In other news, VP Mark Boulding sold 2,813 shares of PTC Therapeutics stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $72.57, for a total transaction of $204,139.41. Following the transaction, the vice president directly owned 105,272 shares of the company’s stock, valued at $7,639,589.04. The trade was a 2.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew Klein sold 10,292 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $68.57, for a total value of $705,722.44. Following the transaction, the chief executive officer owned 383,868 shares of the company’s stock, valued at approximately $26,321,828.76. This trade represents a 2.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 77,370 shares of company stock worth $5,322,261 over the last ninety days. 5.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On PTC Therapeutics

Several large investors have recently added to or reduced their stakes in PTCT. BlackRock Inc. bought a new stake in shares of PTC Therapeutics during the 2nd quarter valued at $1,139,089,000. Jupiter Topco LLC bought a new position in PTC Therapeutics in the 2nd quarter worth $590,182,000. Janus Henderson Group PLC boosted its holdings in PTC Therapeutics by 48.3% in the 1st quarter. Janus Henderson Group PLC now owns 7,193,433 shares of the biopharmaceutical company’s stock worth $489,997,000 after buying an additional 2,342,101 shares during the period. Wellington Management Group LLP boosted its holdings in PTC Therapeutics by 4.7% in the 2nd quarter. Wellington Management Group LLP now owns 4,128,273 shares of the biopharmaceutical company’s stock worth $336,743,000 after buying an additional 185,663 shares during the period. Finally, Bank of America Corp DE increased its stake in PTC Therapeutics by 31.8% in the 1st quarter. Bank of America Corp DE now owns 1,886,841 shares of the biopharmaceutical company’s stock worth $128,550,000 after buying an additional 455,284 shares in the last quarter.

Trending Headlines about PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Raised 2026 outlook and strong revenue growth: PTC reported third-quarter revenue of approximately $358 million, up 69.6% year over year, including $276 million in product revenue. Management increased full-year 2026 revenue guidance to $1.29 billion-$1.32 billion and product revenue guidance to $960 million-$990 million. Sephience revenue reached $182 million, supported by U.S. growth and international expansion. PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Analysts raised price targets: TD Cowen lifted its target from $90 to $95 and maintained a “buy” rating. Wells Fargo raised its target from $109 to $112 and kept an “overweight” rating, signaling substantial potential upside based on the current valuation. TD Cowen recommendations Wells Fargo price target update
• Positive Sentiment: Pipeline expansion: PTC acquired ST-920, a Fabry disease gene therapy, and expects to complete its biologics license application submission in the fourth quarter, adding a potential future growth catalyst. PTC corporate update
• Neutral Sentiment: Royal Bank of Canada raised its price target from $75 to $77 but retained a “sector perform” rating, indicating improved valuation expectations without a bullish change in its recommendation. RBC recommendations
• Negative Sentiment: Quarterly loss weighed on sentiment: PTC reported a GAAP loss of $0.62 per share, versus analysts’ expected profit of $0.14. Although revenue exceeded estimates, the earnings miss and swing from a year-earlier profit create near-term concern. Some reports cite adjusted earnings of $0.61 per share, highlighting a difference in reporting methodology. PTC Therapeutics swings to Q3 loss

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.